42 results about "Osteocalcin" patented technology

The invention discloses a bone calcium extraction method capable of reducing fat content, and osteocalcin prepared by the method. The method comprises the following steps of three times of derosination, twice centrifugation and a two-stage protease hydrolysis. Fat in bone powder prepared by the derosination process of the invention is completely removed basically, allowing the fat content in the calcium preparation obtained by enzymatic hydrolysis to be lower than 0.1%. The product is safer and healthier for consumers with cardiovascular diseases, but does not increase economic burden.

The invention relates to a method of identifying a compound that affects osteocalcin activity, comprising obtaining a 3D structure of osteocalcin or a fragment thereof, designing a compound to interact with, or mimic, the 3D structure of osteocalcin or fragment thereof, obtaining the compound, and determining whether the compound affects osteocalcin activity.

The present invention relates to a Chinese medicine for curing osteoporous-compound kidney-tonifying bone-strengthening Chinese medicine mixture. Said medicine is made up by using 7 Chinese medicinalmaterials of psoralea fruit, drynaria rhizome, epimedium, rehmannia root, codonopsis root, astragalus root and schisandra berry as raw material, and can obtain the obvious therapeutic effect.

The invention discloses a molecular biological method for predicting height of excellent skiers and skaters through detection of osteocalcin content in serum. According the invention, enzyme labeled immunosorbent assay is used to detect and compare expression quantities of osteocalcin in bloods of excellent skiers and skaters and of ordinary people, and since osteocalcin acts on osteoblasts to further influence the height of a person, optimum height of excellent skiers and skaters can be indirectly predicted through the expression level of osteocalcin. Detection results of enzyme labeled immunosorbent assay show that the concentration of osteocalcin in the bloods of excellent skiers and skaters is in a range of 1.50 + / - 0.76 nmol / L, higher than the concentration of osteocalcin in the bloods of ordinary people as the concentration of osteocalcin in the bloods of ordinary people is 1.48 + / - 0.58 nmol / L. Thus, it is proved that high osteocalcin content in serum can be used for judgment of optimum height of excellent skiers and skaters. The molecular biological method provided by the invention lays a solid theoretical and technical foundation for establishment of a scientific system of early prediction and evaluation of potential of skiers and skaters, talent selection and talent training, increases the success rate of talent selection and makes a breakthrough to theoretical and technical difficulties in one-shot talent selection.

An application of fully carboxylated osteocalcin in preparing a fast-acting antidepressant. The fully carboxylated osteocalcin is administered at a concentration of 80 ng / g.

The invention discloses an osteocalcin (OC) freeze-dried powder preparation for injection. The OC freeze-dried powder preparation consists of OC and medically acceptable pharmaceutical adjuvants, wherein the medically acceptable pharmaceutical adjuvants comprise mannitol, vitamin C, n-dodecyl-beta-D-maltoside and zinc carbonate in the mass ratio of 1: (0.2-0.8):(0.1-0.5):(0.04-0.1), and the mass ratio of mannitol to OC is (0.5-1.0):1. The OC freeze-dried powder preparation for injection has the advantages of good stability, plump appearance, as well as no degradation, aggregation or conformational change under accelerated test conditions and good in-vivo safety. After the freeze-dried powder is given to mice intravenously, bioavailability of the freeze-dried powder is measured to be up to 67.4%-79.2%.

A composition and a kit are capable of detecting osteocalcin and N-cadherin, which are biomarkers of circulating osteocalcin-positive cells that are released in the microscopic bone metastasis stage of cancer. Thus, the composition and the kit may diagnose metastatic bone cancer early. In addition, a method of providing information for early diagnosis of bone metastasis of cancer may increase the survival rate of metastatic bone cancer patients.

The invention discloses the use of osteocalcin to prepare Parkinson's disease treatment drug; the invention finds that exogenous administration of osteocalcin can improve the motor dysfunction of the Parkinson's disease rat model and alleviate its nigrostriatum Loss of dopaminergic neurons can alleviate PC12 cell apoptosis caused by 6‑OHDA through the AKT / GSK pathway in vitro. Therefore, osteocalcin, as a small molecule polypeptide hormone that can pass through the blood-brain barrier, can become a new drug for preventing and treating Parkinson's disease.

The invention belongs to the field of medicine in-vitro diagnosis, and particularly relates to a calibration product of an osteocalcin detection reagent and a preparation method thereof. Due to addingof a composite protection substance composed of an excipient, a surfactant, a stabilizer and a preservative, the calibration product is high in stability and can be stable for one month at room temperature, can be stable at 20 DEG C for one year; the preparation method can trace to international or national reference substance, so that accuracy of clinical result. The calibration product is suitable for industrial large-scale production, the problem that existing calibration products are unstable in preservation is solved, and production cost is lowered.

The invention encompasses compositions and methods for effectively treating and / or preventing the development and / or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and / or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts. The inventive compositions used for administration to human and other mammalian subjects having or at risk for development of osteoporosis comprise (1) at least one agent capable of modulating expression and / or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT / enhancer binding protein-α (C / EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent that activates expression and / or activity of one or more of the osteogenic transcription factors (Runx2 / Cbfα1, Dlx5, Osterix, Msx2); (3) at least one agent that activates expression and / or activity of one or more of bone morphogenetic proteins (BMPs: BMP 2 and 4), alkaline phosphatase (ALP), and osteocalcin; (4) at least one agent capable of activating Wnt / β-catenin signaling pathway; (5) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (6) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); and (7) at least one agent that induces the expression of and / or activates one or more of adenosine monophosphate-activated protein kinase (AMPK), sirtuin (SIRT1) and adiponectin (AP).

The invention relates to a detection reagent and a detection method for osteogenic potential of mesenchymal stem cells, and the detection method comprises the step of determining the osteogenic potential of mesenchymal stem cells by detecting the expression quantity of osteocalcin and human RUNX family transcription factor 2 in osteogenic induction of mesenchymal stem cells. According to the method for detecting the osteogenic potential of the mesenchymal stem cells, the osteogenic potential of the mesenchymal stem cells is determined by detecting the expression quantity of osteocalcin and a human RUNX family transcription factor 2 in osteogenic induction of the mesenchymal stem cells, the osteogenic potential of the mesenchymal stem cells can be determined through specific gene expression detection in the early and middle stages of induced differentiation, and the osteogenic potential of the to-be-detected mesenchymal stem cells is known, so that the method has important significance on the osteogenic induction culture process of the mesenchymal stem cells.